Documents & Resources

Incorporating GIVIMP Recommendations into Method Development, Use, and Transfer

The demand for toxicology data from human-relevant, New Approach Methodologies (NAMs) continues to increase. Fortunately, the scientific community has responded with new tools based on human tissues and cells. The creators of these systems and test methods utilizing them have invested in their development and also in studies designed to demonstrate their relevance, reproducibility, and transferability. Despite these efforts, scientific confidence in these methods at the regulatory level remains comparatively low. (more…)

Multiscale Stiffness of Human Emphysematous Precision-Cut Lung Slices

IIVS is excited to announce a new publication in Science with co-authors at Boston University and Mechanobiologix (Newton, MA, USA)! Abstract: Emphysema is a debilitating disease that remodels the lung leading to reduced tissue stiffness. Thus, understanding emphysema progression requires assessing lung stiffness at both the tissue and alveolar scales. (more…)

IIVS Financial Conflict of Interest in Research Policy

IIVS Posters – SOT 2023 Annual Meeting

IIVS presented several posters at SOT 2023. This post includes links to the full PDF versions of each poster presented. (more…)

Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters

The Institute for In Vitro Sciences (IIVS) is sponsoring a series of workshops to identify, discuss and develop recommendations for optimal scientific and technical approaches for conducting in vitro assays, to assess potential toxicity within and across tobacco and various next generation nicotine and tobacco products (NGPs), including heated tobacco products (HTPs) and electronic nicotine delivery systems (ENDS). (more…)

Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 2

This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan...

Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 1

This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan...

Good In Vitro Method Practices Certification: A Roadmap for Implementation and Harmonization

IIVS is Pleased to Announce the Co-Publication of Three Articles

IIVS is pleased to announce the co-publication of several respiratory-based articles highlighting: the characterization and recommendations for non-animal techniques used to model mucociliary clearance in human-derived test systems, the dosimetry of tobacco products for in vitro testing and a third article covering the use of New Approach Methodologies to nicotine containing products in a regulatory environment.

Key Challenges for In Vitro Testing of Tobacco Products for Regulatory applications: Recommendations for Dosimetry

Ciliary Beat Frequency: Proceedings and Recommendations from a Multi-laboratory Ring Trial Using 3-D Reconstituted Human Airway Epithelium to Model Mucociliary Clearance

Eye Irritation Testing and Beyond

If you missed the webinar: Establishing Scientific Confidence in New Approach Methodologies (NAMs): Eye Irritation Testing and Beyond, co-sponsored by the Risk Assessment and In Vitro and Alternative Methods Specialty Sections of SOT, a recording is now posted. Speakers included Hans Raabe (IIVS) and Dr. Amy Clippinger...